Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.